Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:54 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:54 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.
Cardinal Health (CAH) to Extend Warehouse Footing With New Center
by Zacks Equity Research
Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.
BD's (BDX) Latest Product to Transform Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Accuray's (ARAY) New Tie-Up to Augment Treatment Planning
by Zacks Equity Research
Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.
Why Is Masimo (MASI) Up 6.9% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
DexCom (DXCM) to Boost Diabetes Management With New Coverage
by Zacks Equity Research
DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.
Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Here's Why Investors Should Retain Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Stryker's (SYK) Q Guidance System Receives FDA Approval
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.
Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays
by Zacks Equity Research
Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.
Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why Investors Should Retain Illumina (ILMN) Stock Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Integra (IART) Gains From Innovation Amid Cost Constraints
by Zacks Equity Research
Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.
CVS Health (CVS) to Improve Primary Care With New Offering
by Zacks Equity Research
CVS Health (CVS) debuts the new CVS Health Virtual Primary Care solution to allow consumers to obtain care whenever necessary.
NextGen Healthcare (NXGN) Unveils Health Data Hub Insights
by Zacks Equity Research
NextGen Healthcare's (NXGN) newly launched tool can help healthcare providers to receive a complete picture of the community and patient health.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) due to its strong product portfolio.
Walgreens Boots (WBA) Omnichannel Aids Growth Amid Cost Woes
by Zacks Equity Research
The continued acceleration of Walgreens' (WBA) omnichannel offerings and a significant rise in MyWalgreens membership are notable upsides in recent times.